When do biologic drug patents expire and when will biosimilars launch?

US Patent 5,480,640 (Prostate Cancer): What Claims Cover Intraprostatic/Intralesional Alpha Interferon and How Strong Is the US Patent Estate

US 5,480,640 claims methods for treating prostate cancer with alpha interferon delivered directly into the prostate or into the lesion (intraprostatic or intralesional injection). The independent claim is a route-of-administration plus therapeutic use method claim. The dependent claims narrow to full-gland or whole-lesion infiltration, specific alpha interferon species, and a specific once-weekly five-dose escalation regimen for interferon alfa-2b.

What patents cover US 5,480,640’s method: intraprostatic or intralesional alpha interferon for prostate cancer?

Core claimed idea. A prostate cancer treatment method using alpha interferon administered by intraprostatic or intralesional injection.

How claim scope is constructed (claim-by-claim)

Claim 1 (independent): Prostate cancer treatment by administering a therapeutically effective amount of alpha interferon by intraprostatic or intralesional injection.
Claim 2: Intraprostatic injection such that the whole prostate is infiltrated.
Claim 3: Intralesional injection such that the entire lesion is infiltrated.
Claim 4: Alpha interferon selected from:
- interferon alfa-2a
- interferon alfa-2b
- interferon alfa-2c
- interferon alfa-n1
- consensus alfa interferon
- interferon alfa-n3
Claim 5: Alpha interferon is interferon alfa-2b.
Claim 6: Interferon alfa-2b administered once per week for 5 weeks in progressively increasing dosages.
Claim 7: Increasing doses are 1×10^6, 2×10^6, 3×10^6, 4×10^6, 5×10^6 IU.

Practical IP read-through

US 5,480,640 is not a “new interferon molecule” patent. It is a method claim focused on:

Specific use (prostate cancer), and
Specific delivery routes (intraprostatic or intralesional injection), plus
Specific species and dosing regimen in the dependent claims.

That architecture is typical of early-generation oncology method patents: broad enough to capture any alpha interferon species in Claim 1/4, and increasingly narrow in Claims 2-3 and 5-7.

“Around” opportunities created by the claim structure

Even without knowing the full prosecution record, the claim text itself creates predictable design-around vectors:

Use a non-alpha interferon (e.g., interferon gamma or pegylated interferons if not within “alpha interferon” scope).
Change the delivery route (systemic administration, intra-arterial, percutaneous into a surrounding region rather than “intraprostatic or intralesional”).
Treat a different population (e.g., benign prostatic hyperplasia or a different cancer stage) is not a guaranteed carve-out unless “prostate cancer” is construed narrowly in the litigation record.
Avoid the specific regimen (once-weekly 5-week escalation with the enumerated IU amounts). Claims 6-7 are tightly tied to the regimen; Claim 1 remains broader if infringement is asserted on route plus therapeutic use rather than the exact dosing schedule.

What other patent families typically overlap this space

For intralesional/intraprostatic biologic delivery and prostate cancer, the US patent landscape historically includes overlapping claim sets in several clusters:

Prostate cancer therapy using interferons via localized delivery
Prostate cancer therapy using localized injections of biologics (cytokines, viral vectors, immunomodulators)
Device or method claims tied to injection technique, targeting, and distribution within the gland or lesion
Composition/formulation claims for interferon preparations suitable for injection

US 5,480,640 is the “method of treatment by route” anchor for the particular interferon-local injection concept, and it will be functionally adjacent to other localized-delivery and prostate-oncology claims filed by other parties.

The user-supplied prompt requests a comprehensive landscape analysis tied specifically to US 5,480,640. Producing a correct, citation-backed map of which other patents cover the same territory (with numbers, assignees, claim charts, and expiration dates) requires authoritative bibliographic and full-text claim data beyond the claim text provided. Under the operating constraints, this cannot be completed accurately.

What does US 5,480,640 claim, and where are the key infringement pressure points?

Immediate infringement risk concentrates on localized alpha interferon injection into a prostate cancer lesion or prostate tissue.

Claim 1: route plus therapeutic use

Infringement elements (as written):
1. Treating cancer of the prostate
2. Administering a therapeutically effective amount of alpha interferon
3. By intraprostatic or intralesional injection

Pressure points for proving infringement

Whether the injected material is “alpha interferon” as construed (species list appears in Claim 4).
Whether the injection qualifies as “intraprostatic” or “intralesional.” Courts typically examine actual anatomical injection location and technique.
Whether the clinical protocol qualifies as “therapeutically effective” in the therapeutic sense. In litigation, this often becomes a question of whether the regimen is intended to treat prostate cancer and has clinical rationale and effect.

Claims 2 and 3: “whole prostate” and “entire lesion”

Claim 2: intraprostatic injection “such that the whole prostate is infiltrated.”
Claim 3: intralesional injection “such that the entire lesion is infiltrated.”

Critical narrowing These phrases create factual issues. If the treatment protocol injects only part of the prostate or targets a lesion partially, an accused regimen may argue non-infiltration or incomplete coverage.

Claims 4-5: specific alpha interferon species

Claim 4 gives a defined list of alpha interferon variants. Claim 5 narrows to interferon alfa-2b.

This is helpful for enforcement because it limits “alpha interferon” arguments to enumerated types if the patentee framed “alpha interferon” as these variants in claim interpretation.

Claims 6-7: specific 5-week escalation dosing

Once per week for 5 weeks
Progressively increasing doses: 1×10^6 to 5×10^6 IU in increments.

Most design-around friendly Accused products or protocols can avoid this narrow claim by:

using different time intervals,
using a different escalation pattern,
using a flat dose,
using different IU amounts,
or not using interferon alfa-2b (instead using alfa-2a or other variants listed in Claim 4).

When does US 5,480,640 lose exclusivity, and how does that timing affect generic or biosimilar risk?

No exclusivity timeline can be calculated accurately from the prompt alone because the filing date, priority, patent term adjustments, and any terminal disclaimers are not provided. Under the operating constraints, this cannot be completed without accurate bibliographic data.

What generic entry risks exist for intraprostatic/intralesional alpha interferon under US 5,480,640?

Because US 5,480,640 is a method-of-use and route-delivery claim, generic “entry” analysis depends less on whether an alpha interferon molecule is available and more on whether an accused clinical protocol practices the claimed method.

Molecule availability versus method infringement

Alpha interferons have historically been available as drugs with generic and biosimilar pathways depending on the product type and biologic status.
Even if an interferon becomes available through abbreviated approvals or biosimilar pathways, practicing a claimed method in the US can still infringe if the method is performed without license.

The likely litigation focus

In a protocol-based dispute, the main questions are:

location of injection (intraprostatic vs intralesional),
target coverage (“whole prostate” or “entire lesion”),
interferon type (alpha species),
and dosing schedule (especially the strict 5-dose escalation in Claims 6-7).

How strong is the patent estate behind localized alpha interferon injections for prostate cancer?

Strength assessment is limited by the prompt’s scope. US 5,480,640’s claim language indicates:

breadth in Claim 1 (any alpha interferon, therapeutically effective amount, localized injection),
moderate narrowing in Claims 2-3 (whole prostate/lesion infiltration),
and high narrowing in Claims 6-7 (specific interferon alfa-2b regimen).

But evaluating overall estate strength requires:

related patents by the same assignee,
whether continuations exist,
whether dependent claims are supported by a robust specification enabling broad interpretation,
whether there is prior art overlap or invalidation risk.

Without the rest of the estate and prosecution history, a definitive strength score cannot be produced under the constraints.

What patent litigation affects US 5,480,640’s enforceability?

A correct treatment of litigation status requires case captions, dockets, rulings, settlements, and appeal outcomes. None are provided, and a landscape build would require external case retrieval. Under the operating constraints, this section cannot be completed.

What formulations are protected by US 5,480,640?

The claim set provided is method-focused and does not specify a formulation component (e.g., excipients, concentration, reconstitution media) as an element of Claims 1-7. Any formulation protection would depend on dependent claims not shown and/or additional patents in the family, which are not provided.

How does US 5,480,640 compare with other localized prostate cancer biologic injection approaches?

Within the boundaries of the provided claim language, US 5,480,640 is distinguished by:

alpha interferon as the active, and
direct localized injection into prostate tissue or the lesion.

Competing approaches in this space typically pivot on:

different immunotherapies (other cytokines, checkpoint modulators, vaccines, oncolytic therapies),
different biologics,
different delivery routes (systemic, intratumoral but non-prostate-specific, or imaging-guided targeted delivery with different procedural steps).

Without additional patents and claim texts, no direct claim-by-claim comparison can be completed.

What is the Orange Book status of US 5,480,640, and does it map to an FDA-labeled product?

No Orange Book mapping can be stated from the prompt alone. Orange Book status is label-and-listed-product driven, and method patents require a correct FDA product linkage that is not provided.

Key Takeaways

US 5,480,640 claims prostate cancer treatment methods using localized injection of alpha interferon into the prostate (intraprostatic) or into a lesion (intralesional).
The independent claim (Claim 1) is broad on route and interferon type; dependent claims narrow coverage to whole-prostate or whole-lesion infiltration, specific alpha interferon species, and a tight interferon alfa-2b five-week escalating dose regimen.
Enforcement and infringement risk are driven by clinical protocol facts: injection location, target coverage, interferon variant, and dosing schedule.
A complete US patent landscape, litigation impact analysis, exclusivity timeline, Orange Book status, and estate strength cannot be produced accurately from the prompt alone without bibliographic and external record data.

FAQs

Does US 5,480,640 require “infiltration” of the whole prostate to infringe Claim 2?
Claim 2 expressly requires whole-prostate infiltration as written; Claim 1 does not add the whole-prostate phrase.
Can a different interferon alpha variant avoid Claims 5-7 while still risking Claim 1 or Claim 4?
Yes, Claims 5-7 are specific to interferon alfa-2b and a five-week regimen; however Claim 1 and Claim 4 can still cover other alpha interferon variants if used with the claimed route and therapeutic purpose.
Is changing from once-weekly dosing to a different schedule enough to avoid infringement?
It avoids the narrowness of Claims 6-7 but may still leave exposure under Claim 1 if the route and therapeutic use elements are met.
What is the most likely litigation dispute under US 5,480,640?
Disputes typically center on whether the injection procedure qualifies as intraprostatic/intralesional and whether the asserted protocol targets the “whole prostate” or “entire lesion” in the dependent-claim scenarios.
How do biosimilars affect US 5,480,640 risk?
Biosimilar availability of alpha interferon affects supply but not method infringement; risk persists if physicians or entities practice the claimed localized method without authorization.

References

No sources were cited because no authoritative bibliographic or external litigation/Orange Book record data was provided in the prompt.

Title:	Alpha interferon for treating prostate cancer
Abstract:	Described is a method for treating carcinoma of the prostate using recombinant human alpha interferon via intraprostatic or intralesional injection.
Inventor(s):	Morales; Alvaro (Kingston, CA), Wilson; James W. L. (Kingston, CA)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	08/432,742
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 5,480,640 (Prostate Cancer): What Claims Cover Intraprostatic/Intralesional Alpha Interferon and How Strong Is the US Patent Estate US 5,480,640 claims methods for treating prostate cancer with alpha interferon delivered directly into the prostate or into the lesion (intraprostatic or intralesional injection). The independent claim is a route-of-administration plus therapeutic use method claim. The dependent claims narrow to full-gland or whole-lesion infiltration, specific alpha interferon species, and a specific once-weekly five-dose escalation regimen for interferon alfa-2b. What patents cover US 5,480,640’s method: intraprostatic or intralesional alpha interferon for prostate cancer? Core claimed idea. A prostate cancer treatment method using alpha interferon administered by intraprostatic or intralesional injection. How claim scope is constructed (claim-by-claim) Claim 1 (independent): Prostate cancer treatment by administering a therapeutically effective amount of alpha interferon by intraprostatic or intralesional injection. Claim 2: Intraprostatic injection such that the whole prostate is infiltrated. Claim 3: Intralesional injection such that the entire lesion is infiltrated. Claim 4: Alpha interferon selected from: interferon alfa-2a interferon alfa-2b interferon alfa-2c interferon alfa-n1 consensus alfa interferon interferon alfa-n3 Claim 5: Alpha interferon is interferon alfa-2b. Claim 6: Interferon alfa-2b administered once per week for 5 weeks in progressively increasing dosages. Claim 7: Increasing doses are 1×10^6, 2×10^6, 3×10^6, 4×10^6, 5×10^6 IU. Practical IP read-through US 5,480,640 is not a “new interferon molecule” patent. It is a method claim focused on: Specific use (prostate cancer), and Specific delivery routes (intraprostatic or intralesional injection), plus Specific species and dosing regimen in the dependent claims. That architecture is typical of early-generation oncology method patents: broad enough to capture any alpha interferon species in Claim 1/4, and increasingly narrow in Claims 2-3 and 5-7. “Around” opportunities created by the claim structure Even without knowing the full prosecution record, the claim text itself creates predictable design-around vectors: Use a non-alpha interferon (e.g., interferon gamma or pegylated interferons if not within “alpha interferon” scope). Change the delivery route (systemic administration, intra-arterial, percutaneous into a surrounding region rather than “intraprostatic or intralesional”). Treat a different population (e.g., benign prostatic hyperplasia or a different cancer stage) is not a guaranteed carve-out unless “prostate cancer” is construed narrowly in the litigation record. Avoid the specific regimen (once-weekly 5-week escalation with the enumerated IU amounts). Claims 6-7 are tightly tied to the regimen; Claim 1 remains broader if infringement is asserted on route plus therapeutic use rather than the exact dosing schedule. What other patent families typically overlap this space For intralesional/intraprostatic biologic delivery and prostate cancer, the US patent landscape historically includes overlapping claim sets in several clusters: Prostate cancer therapy using interferons via localized delivery Prostate cancer therapy using localized injections of biologics (cytokines, viral vectors, immunomodulators) Device or method claims tied to injection technique, targeting, and distribution within the gland or lesion Composition/formulation claims for interferon preparations suitable for injection US 5,480,640 is the “method of treatment by route” anchor for the particular interferon-local injection concept, and it will be functionally adjacent to other localized-delivery and prostate-oncology claims filed by other parties. The user-supplied prompt requests a comprehensive landscape analysis tied specifically to US 5,480,640. Producing a correct, citation-backed map of which other patents cover the same territory (with numbers, assignees, claim charts, and expiration dates) requires authoritative bibliographic and full-text claim data beyond the claim text provided. Under the operating constraints, this cannot be completed accurately. What does US 5,480,640 claim, and where are the key infringement pressure points? Immediate infringement risk concentrates on localized alpha interferon injection into a prostate cancer lesion or prostate tissue. Claim 1: route plus therapeutic use Infringement elements (as written): Treating cancer of the prostate Administering a therapeutically effective amount of alpha interferon By intraprostatic or intralesional injection Pressure points for proving infringement Whether the injected material is “alpha interferon” as construed (species list appears in Claim 4). Whether the injection qualifies as “intraprostatic” or “intralesional.” Courts typically examine actual anatomical injection location and technique. Whether the clinical protocol qualifies as “therapeutically effective” in the therapeutic sense. In litigation, this often becomes a question of whether the regimen is intended to treat prostate cancer and has clinical rationale and effect. Claims 2 and 3: “whole prostate” and “entire lesion” Claim 2: intraprostatic injection “such that the whole prostate is infiltrated.” Claim 3: intralesional injection “such that the entire lesion is infiltrated.” Critical narrowing These phrases create factual issues. If the treatment protocol injects only part of the prostate or targets a lesion partially, an accused regimen may argue non-infiltration or incomplete coverage. Claims 4-5: specific alpha interferon species Claim 4 gives a defined list of alpha interferon variants. Claim 5 narrows to interferon alfa-2b. This is helpful for enforcement because it limits “alpha interferon” arguments to enumerated types if the patentee framed “alpha interferon” as these variants in claim interpretation. Claims 6-7: specific 5-week escalation dosing Once per week for 5 weeks Progressively increasing doses: 1×10^6 to 5×10^6 IU in increments. Most design-around friendly Accused products or protocols can avoid this narrow claim by: using different time intervals, using a different escalation pattern, using a flat dose, using different IU amounts, or not using interferon alfa-2b (instead using alfa-2a or other variants listed in Claim 4). When does US 5,480,640 lose exclusivity, and how does that timing affect generic or biosimilar risk? No exclusivity timeline can be calculated accurately from the prompt alone because the filing date, priority, patent term adjustments, and any terminal disclaimers are not provided. Under the operating constraints, this cannot be completed without accurate bibliographic data. What generic entry risks exist for intraprostatic/intralesional alpha interferon under US 5,480,640? Because US 5,480,640 is a method-of-use and route-delivery claim, generic “entry” analysis depends less on whether an alpha interferon molecule is available and more on whether an accused clinical protocol practices the claimed method. Molecule availability versus method infringement Alpha interferons have historically been available as drugs with generic and biosimilar pathways depending on the product type and biologic status. Even if an interferon becomes available through abbreviated approvals or biosimilar pathways, practicing a claimed method in the US can still infringe if the method is performed without license. The likely litigation focus In a protocol-based dispute, the main questions are: location of injection (intraprostatic vs intralesional), target coverage (“whole prostate” or “entire lesion”), interferon type (alpha species), and dosing schedule (especially the strict 5-dose escalation in Claims 6-7). How strong is the patent estate behind localized alpha interferon injections for prostate cancer? Strength assessment is limited by the prompt’s scope. US 5,480,640’s claim language indicates: breadth in Claim 1 (any alpha interferon, therapeutically effective amount, localized injection), moderate narrowing in Claims 2-3 (whole prostate/lesion infiltration), and high narrowing in Claims 6-7 (specific interferon alfa-2b regimen). But evaluating overall estate strength requires: related patents by the same assignee, whether continuations exist, whether dependent claims are supported by a robust specification enabling broad interpretation, whether there is prior art overlap or invalidation risk. Without the rest of the estate and prosecution history, a definitive strength score cannot be produced under the constraints. What patent litigation affects US 5,480,640’s enforceability? A correct treatment of litigation status requires case captions, dockets, rulings, settlements, and appeal outcomes. None are provided, and a landscape build would require external case retrieval. Under the operating constraints, this section cannot be completed. What formulations are protected by US 5,480,640? The claim set provided is method-focused and does not specify a formulation component (e.g., excipients, concentration, reconstitution media) as an element of Claims 1-7. Any formulation protection would depend on dependent claims not shown and/or additional patents in the family, which are not provided. How does US 5,480,640 compare with other localized prostate cancer biologic injection approaches? Within the boundaries of the provided claim language, US 5,480,640 is distinguished by: alpha interferon as the active, and direct localized injection into prostate tissue or the lesion. Competing approaches in this space typically pivot on: different immunotherapies (other cytokines, checkpoint modulators, vaccines, oncolytic therapies), different biologics, different delivery routes (systemic, intratumoral but non-prostate-specific, or imaging-guided targeted delivery with different procedural steps). Without additional patents and claim texts, no direct claim-by-claim comparison can be completed. What is the Orange Book status of US 5,480,640, and does it map to an FDA-labeled product? No Orange Book mapping can be stated from the prompt alone. Orange Book status is label-and-listed-product driven, and method patents require a correct FDA product linkage that is not provided. Key Takeaways US 5,480,640 claims prostate cancer treatment methods using localized injection of alpha interferon into the prostate (intraprostatic) or into a lesion (intralesional). The independent claim (Claim 1) is broad on route and interferon type; dependent claims narrow coverage to whole-prostate or whole-lesion infiltration, specific alpha interferon species, and a tight interferon alfa-2b five-week escalating dose regimen. Enforcement and infringement risk are driven by clinical protocol facts: injection location, target coverage, interferon variant, and dosing schedule. A complete US patent landscape, litigation impact analysis, exclusivity timeline, Orange Book status, and estate strength cannot be produced accurately from the prompt alone without bibliographic and external record data. FAQs Does US 5,480,640 require “infiltration” of the whole prostate to infringe Claim 2? Claim 2 expressly requires whole-prostate infiltration as written; Claim 1 does not add the whole-prostate phrase. Can a different interferon alpha variant avoid Claims 5-7 while still risking Claim 1 or Claim 4? Yes, Claims 5-7 are specific to interferon alfa-2b and a five-week regimen; however Claim 1 and Claim 4 can still cover other alpha interferon variants if used with the claimed route and therapeutic purpose. Is changing from once-weekly dosing to a different schedule enough to avoid infringement? It avoids the narrowness of Claims 6-7 but may still leave exposure under Claim 1 if the route and therapeutic use elements are met. What is the most likely litigation dispute under US 5,480,640? Disputes typically center on whether the injection procedure qualifies as intraprostatic/intralesional and whether the asserted protocol targets the “whole prostate” or “entire lesion” in the dependent-claim scenarios. How do biosimilars affect US 5,480,640 risk? Biosimilar availability of alpha interferon affects supply but not method infringement; risk persists if physicians or entities practice the claimed localized method without authorization. References No sources were cited because no authoritative bibliographic or external litigation/Orange Book record data was provided in the prompt. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	⤷ Start Trial	2015-05-02
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Start Trial	2015-05-02
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		⤷ Start Trial	2015-05-02
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 5,480,640

Summary for Patent: 5,480,640